Oligodendroglia support axon survival and function through mechanisms independent of myelination, and their dysfunction leads to axon degeneration in several diseases. The cause of this degeneration has not been determined, but lack of energy metabolites such as glucose or lactate has been proposed. Lactate is transported exclusively by monocarboxylate transporters, and changes to these transporters alter lactate production and use. Here we show that the most abundant lactate transporter in the central nervous system, monocarboxylate transporter 1 (MCT1, also known as SLC16A1), is highly enriched within oligodendroglia and that disruption of this transporter produces axon damage and neuron loss in animal and cell culture models. In addition, this same transporter is reduced in patients with, and in mouse models of, amyotrophic lateral sclerosis, suggesting a role for oligodendroglial MCT1 in pathogenesis. The role of oligodendroglia in axon function and neuron survival has been elusive; this study defines a new fundamental mechanism by which oligodendroglia support neurons and axons.
Oligodendroglia support axon survival and function through mechanisms independent of myelination, and their dysfunction leads to axon degeneration in several diseases. The cause of this degeneration has not been determined, but lack of energy metabolites such as glucose or lactate has been proposed. Lactate is transported exclusively by monocarboxylate transporters, and changes to these transporters alter lactate production and use. Here we show that the most abundant lactate transporter in the central nervous system, monocarboxylate transporter 1 (MCT1, also known as SLC16A1), is highly enriched within oligodendroglia and that disruption of this transporter produces axon damage and neuron loss in animal and cell culture models. In addition, this same transporter is reduced in patients with, and in mouse models of, amyotrophic lateral sclerosis, suggesting a role for oligodendroglial MCT1 in pathogenesis. The role of oligodendroglia in axon function and neuron survival has been elusive; this study defines a new fundamental mechanism by which oligodendroglia support neurons and axons.
Oligodendroglia promote rapid conduction of action potentials by ensheathing central nervous system (CNS) axons with myelin. Oligodendrocyte diseases, such as multiple sclerosis and leukodystrophies, have demonstrated demyelination and axon degeneration at autopsy 1,2 . Mouse models of oligodendrocyte injury, including proteolipid protein 1 (Plp1)-null mice 3 and Cnp (also known as Cnp1 and CNPase) mutant mice 4 , demonstrate axon loss without considerable demyelination, suggesting that oligodendroglia support axon survival through a myelin-independent mechanism, possibly as a result of insufficient axonal energy support 5 . Myelinated axons are only exposed to extracellular energy substrates at the nodes of Ranvier, and therefore may require specialized transport of energy metabolites from myelinating oligodendroglia to meet their high metabolic needs. The identity of these metabolites is unclear, but our study suggests that lactate may be essential and its transport dependent on MCT1 ( Supplementary Fig. 1) .
MCT1, along with the transporters MCT2 and MCT4, transport monocarboxylic acids (that is, lactate, pyruvate and ketone bodies), and localize to the CNS 6 . Neurons express MCT2, and glia express both MCT1 and MCT4 (refs 7, 8) , although MCT1 is the dominant glial transporter in the brain 9 . Recently, MCT1 was localized to oligodendroglia and MCT2 to axons of the corpus callosum and cerebellar white matter by immunohistochemistry 10 . In vitro astrocytes produce lactate through aerobic glycolysis 11, 12 , and lactate alone can support neurons in the absence of glucose, presumably through MCT2 localized to neurons. This hypothetical energy transfer was termed the astrocyte-neuron lactate shuttle 13 . Support for lactate-based neuronal support has come from both in vitro and in vivo models 14, 15 ; however, the physiological role for lactate in the non-stressed, uninjured CNS is largely unknown. We now report that oligodendroglia are an important site of MCT1 expression in the brain and spinal cord and are the principal metabolic supplier of lactate to axons and neurons.
Oligodendroglia injury is well established in demyelinating diseases 16 , but the supply of energy metabolites to axons could also be crucial in other neurological diseases. In this study, we investigated amyotrophic lateral sclerosis (ALS), a fatal neurological disease characterized clinically by progressive weakness and pathologically by cortical and spinal motoneuron degeneration. Although the pathogenesis of motoneuron degeneration is unknown, it is mediated partly by surrounding astroglia and microglia 17 . A recent study suggests that grey matter oligodendroglia may be injured in ALS 18 , and we propose that reduced expression of MCT1 is one mechanism by which oligodendroglia produce neurotoxicity in ALS.
MCT1 localizes to oligodendroglia in vivo
Astrocytes 8, 19, 20 , ependymocytes, endothelial cells 19, 21 and recently oligodendroglia 10 have inconsistently been demonstrated to express MCT1. This variability is due to limitations in antibody specificity and/or affinity, along with differences in the species and age of samples analysed. To overcome this technical challenge, we produced two lines of bacterial artificial chromosome (BAC) transgenic mice carrying the tdTomato fluorescent reporter for cellular localization and in vivo expression level of MCT1 messenger RNA in the CNS and peripheral organs ( Fig. 1 and Supplementary Figs 2-4 ). Results are shown for the highest expressing line, although cellular localization was identical for the second line (data not shown). Enrichment of MCT1 mRNA was found within fluorescence-activated cell sorted (FACS) tdTomato-positive cells ( Fig. 1a , group ii), verifying the specificity of the reporter. Expression was similar in perinatal mice, although reporter expression around blood vessels was increased (data not shown). MCT1 BAC mice were crossed with MOBP-eGFP and GLT1-eGFP BAC reporter mice 22 , which express enhanced green fluorescent protein (eGFP) driven by the oligodendrocytespecific myelin-associated oligodendrocyte protein (MOBP) and astrocyte-specific glutamate transporter 1 (GLT1, also known as SLC1A2), respectively. MCT1 mRNA was almost exclusively localized to oligodendroglia in the brain and spinal cord ( Fig. 1 and Supplementary Fig. 3 ), with greater than 70-80% co-localization in the spinal cord, cortex and corpus callosum ( Fig. 1p ). Rare neuronal populations expressed MCT1 ( Supplementary Fig. 4 ), although none in retinal ganglion cells ( Supplementary Fig. 2k ) or spinal cord motoneurons ( Supplementary Fig. 4o, p) . Surprisingly, there was virtually no expression of MCT1 mRNA within adult CNS astrocytes ( Fig. 1 and Supplementary Fig. 3 ), nor was it found in NG2 cells, endothelial cells or microglia ( Fig. 1 ). Most MCT1 BAC-positive cells co-labelled with an oligodendroglia lineage marker, oligodendrocyte transcription factor 2 (OLIG2; Fig. 1l ) 23 , and few other CNS cells expressed tdTomato ( Fig. 1p ).
MCT1 protein also co-localized with myelinating oligodendroglia, as MCT1 immunoreactivity co-localized with myelin basic protein (MBP) and the oligodendrocyte-specific marker 29,39-cyclic-nucleotide 39-phosphodiesterase (CNP) in rodent and human brain (Supplementary Fig. 5 ). MCT1 protein was closely aligned with axons (Supplementary Fig. 5h -j), but not astroglia, axonal nodes or paranodes ( Supplementary Fig. 5k -p). In vitro, NG2 cells and primary oligodendroglia both expressed the MCT1-tdTomato reporter (Supplementary Fig. 6a -f), as do primary astrocyte cultures ( Supplementary  Fig. 6g -l) 24 , which may account for the discrepancies in MCT1 localization in the literature.
The cell specificity and enrichment of native MCT1 mRNA was further evaluated by FACS and BAC translating ribosome affinity purification (BacTRAP) techniques. MCT1 mRNA, quantified by real-time PCR with reverse transcription (real-time RT-PCR) of acutely isolated mouse brain mRNA from FACS and BacTRAP astrocytes and oligodendroglia, was expressed at 16-fold (FACS) and 31-fold (BacTRAP) higher levels in mature oligodendroglia than in astrocytes ( Fig. 1q ). MCT1 expression ( Fig. 1r ) and functional lactate transport ( Fig. 1s) were also detected and enriched in oligodendrocyte tumour cells (that is, oligodendroglioma) as compared with astrocyte tumour cells (that is, astrocytoma). Although not detectable by either the MCT1-tdTomato BAC reporter mice or immunohistochemistry, FACS and BacTRAP experiments suggest that astrocytes express very low levels of MCT1 mRNA in vivo; although it is clear that MCT1 expression and lactate transport is much greater in oligodendroglia than astrocytes. Astrocytes in vivo express the MCT4 lactate transporter (Yo.L., unpublished observations) 25, 26 , suggesting that this transporter may have a more important role in astrocytes than MCT1.
Neuronal survival in vitro requires MCT1
Similar to in vivo, MCT1 mRNA is primarily localized to oligodendrocytelineage cells, immunostained with OLIG2, in postnatal organotypic spinal cord cultures ( Supplementary Fig. 7 ). To investigate whether downregulation or inhibition of MCT1 produces neuron death, organotypic spinal cord cultures were treated with antisense oligonucleotides (ASO) or a specific MCT1 transport inhibitor (MCT1i; Supplementary Fig. 7i ) 27 . After three weeks of treatment, only 67% 6 6.7 (mean 6 s.e.m.) of motoneurons survived in the ASO group (P , 0.01, Fig. 2a , b), and 66% 6 5.9 in the MCT1i group (P , 0.05, Fig. 2c ). Thus, genetic or pharmacological reduction of MCT1 led to motoneuron death.
If the function of MCT1 is to export lactate from oligodendroglia and provide energy metabolites to neurons, then neurons exposed to glucose-free media or stimuli that increase neuronal activity should be particularly vulnerable. Motoneurons in organotypic spinal cord slice cultures were resistant to short periods (2 h) of glucose deprivation, . e, f, Propidium iodide uptake in slice cultures treated with 2 h glucose deprivation plus MCT1i (e; n 5 79, 14, 14, 39, 45 and 10 sections for control, 10 29 , 10 28 , 10 27 , 10 26 and 10 25 MCT1i, respectively) or 2 h glucose deprivation with or without MCT1i and 20 mM lactate (f; n 5 15 for all groups). g, h, Propidium iodide uptake in slices treated with glucose deprivation and MCT1i, labelled with a neuronal (g; NeuN, co-localized cells marked with arrowheads) or an oligodendroglia (h; OLIG2) marker. Scale bars, 20 mm. i, Percentage of propidium iodidelabelled cells co-localizing with cell-specific markers (n 5 11, 10, 10 and 11 sections for NeuN, OLIG2, ALDH1L1 (an astrocyte marker) and IBA1, respectively). Error bars denote s.e.m. *P , 0.05; **P , 0.01.
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presumably owing to the presence of glycogen stores in astrocytes 28 . Simultaneous exposure to glucose deprivation and MCT1i led to concentration-dependent motoneuron loss, as measured by counts of neurofilament-containing neurons in the ventral horn (P , 0.01, Fig. 2d ), and overall cell death, as measured by propidium iodide uptake (P , 0.001, Fig. 2e ). Propidium iodide uptake occurred mainly within neurons (P , 0.001, Fig. 2g , i and Supplementary Fig. 7 ) and occasionally within IBA1-positive microglia ( Fig. 2i and Supplementary Fig. 7 ). Much of the propidium iodide uptake in microglia is probably due to phagocytosing dead cells; however, limited microglia death cannot be excluded. Importantly, there was no death of oligodendrocyte-lineage cells or astrocytes after glucose deprivation and treatment with MCT1i ( Fig. 2h, i and Supplementary Fig. 7 ). Other neurons were also vulnerable to glucose deprivation and MCT1i treatment, as considerable propidium iodide uptake was seen in the dorsal horn of the spinal cord and in organotypic cultures from neocortex ( Supplementary Fig. 7 ). MCT1i-and glucose deprivation-induced neurodegeneration was completely prevented by supplementing media with 20 mM L-lactate (P , 0.01, Fig. 2f ), confirming that the toxicity in cultures was due to reduced lactate release from oligodendroglia, not blockage of lactate uptake on neurons or oligodendroglia. Cell death was also produced by co-treatment of organotypic spinal cord cultures with MCT1i and either glutamate or the GABA (c-aminobutyric acid) antagonist, bicuculline, both of which depolarize neurons in slice cultures (P , 0.05, Supplementary Fig. 8 ) 29, 30 . Because glutamate is also a substrate of metabolism, we confirmed that cell death was dependent on neuron depolarization by blocking cell death with the AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and kainate receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) ( Supplementary Fig. 8 ). In summary, neurons in vitro are vulnerable to inhibitors of MCT1 lactate transport. Toxicity is potentiated by removing glucose or increasing the metabolic activity of neurons, and is prevented by supplying exogenous lactate.
Downregulation of MCT1 in vivo is motoneuron toxic
To downregulate MCT1 in vivo, we produced a lentivirus that expressed GFP and MCT1 short hairpin RNA (shRNA) driven by the cytomegalovirus (CMV) and H1 promoters, respectively (lenti-shRNA). Lenti-shRNA downregulated MCT1 protein both in cultured cells and cervical spinal cord in vivo (Fig. 3a ). The amount of downregulation in vivo is underestimated by western blot because only a fraction of oligodendroglia are transfected by virus. Controls included injection of a lentivirus expressing GFP only (lenti-GFP) and contralateral injections of virus media. Both of the lentiviruses (lenti-shRNA and lenti-GFP) effectively transduced oligodendroglia and astrocytes (Fig. 3b, c) . Four weeks after cervical spinal cord injection of lenti-shRNA, 56% 6 5.7 (n 5 10, P , 0.05) of motoneurons near the injection site survived relative to contralateral media injection, whereas injection of lenti-GFP had no significant effect ( Fig. 3 , P . 0.05). In addition, numerous pathological axonal swellings, immunoreactive for the neurofilament marker SMI-32, resulted from lenti-shRNA treatment ( Fig. 3g ). As expected, motoneuron death in lenti-shRNA-injected spinal cords produced microglial activation, which was not seen using the lenti-GFP control ( Fig. 3h , i). Thus, subacute downregulation of MCT1 focally in the spinal cord is sufficient to produce motoneuron death.
Heterozygous MCT1-null mice develop CNS axonopathy MCT1 shRNA treatment was neurotoxic, and we postulated that reducing expression of MCT1 in a null mouse would also produce neurodegeneration. Complete absence of MCT1 is embryonically lethal, but heterozygous-null mice (MCT1 1/2 ), with ,50% reduction in MCT1, breed and mature normally with no gross phenotypic abnormalities. The mice eventually developed an axonopathy in the brain and spinal cord by 8 months of age, with axon swellings visualized by both light and electron microscopy ( Fig. 4 and Supplementary Fig. 9 ). Notably, axon pathology in these mice is similar to Cnp-null mice 31 , SOD1 transgenic mice as a model of ALS 32 , and to patients with ALS 33 ARTICLE RESEARCH Supplementary Fig. 9 ), there was no change in overall myelination in MCT1 1/2 mice ( Supplementary Fig. 9a-f ), suggesting that the pathology was not secondary to oligodendrocyte injury. In the optic nerve, a pure sample of CNS axons the function of which is partly dependent on lactate 34 , large and intermediate sized degenerating axons were observed in MCT1 1/2 mice (Fig. 4o ). Overall, 1.74 6 0.06% of optic nerve axons from MCT1 1/2 mice showed morphologic features of degeneration, including swellings, enlarged mitochondria and reduced axon diameter, which were not seen in age-matched littermate control mice ( Fig. 4 and Supplementary Fig. 9 ). Notably, oligodendrocyte morphology ( Fig. 4p ) and number were not changed, nor was myelination as represented by normal g-ratios (the ratio between the diameter of the inner axon and the total out diameter) (Fig. 4r ), and intact myelin in nondegenerating axons ( Supplementary Fig. 9 ), again suggesting that axonal degeneration was not due to oligodendrocyte damage or demyelination. Thus, despite only having a partial reduction in MCT1 expression ( Supplementary Fig. 9j ), adult MCT1 1/2 mice demonstrate widespread CNS axonopathy. Given the low percentage of axons affected, it is not surprising that this axonopathy did not produce a behavioural phenotype, loss of motoneurons ( Fig. 4s ), or obvious injury to retinal ganglion cells ( Supplementary Fig. 9t , u) in MCT1 1/2 mice. In summary, MCT1 1/2 mice develop axon degeneration in the CNS without demyelination or oligodendrocyte injury, suggesting that MCT1 is crucial for the normal function of CNS axons through a myelin-independent mechanism.
Oligodendrocyte-specific MCT1 loss causes axonopathy
Although MCT1 is primarily expressed within oligodendroglia in the CNS, it is not exclusive to oligodendroglia and thus we cannot exclude the possibility that the axon degeneration seen in MCT1 1/2 mice is due to downregulating MCT1 in other cell types. To investigate this, we produced two lentiviral constructs that downregulate MCT1 selectively in oligodendroglia through different mechanisms. First, lentiviral constructs were produced that expressed either the same MCT1 shRNA used in Fig. 3 plus GFP (lenti-MBP-shRNA) or GFP alone (lenti-MBP-GFP) driven by the MBP promoter. Lenti-MBP-shRNA downregulated MCT1 protein in the optic nerve ( Fig. 5a, b ) despite transfecting only a small segment of nerve ( Fig. 5c, d) . Transfection was selective for oligodendrocyte-lineage cells, as seen by co-localization of all GFP-labelled cells with OLIG2 ( Fig. 5e , f, arrows) and not astroglia ( Fig. 5c, d) . At the injection site, there were a few pathologically enlarged SMI-32-positive axons in lenti-MBP-GFP-injected optic nerves owing to nerve trauma (Fig. 5g , arrowheads), but markedly more in optic nerves injected with lenti-MBP-shRNA ( Fig. 5h, arrowheads) . Distal to the injection, there were increased degenerating axons, both myelin ovoids (arrows) and 'dark axons' (asterisks), in optic nerve injected with lenti-MBP-shRNA compared with lenti-MBP-GFP ( Fig. 5i-l) . Restricted penetration of the lentivirus into the nerve led to some variability in axon degeneration. Nevertheless, there was a significant increase in the number of degenerating fibres in optic nerves injected with lenti-MBP-shRNA compared with lenti-MBP-GFP (P , 0.05, n 5 4 nerves, Fig. 5m, n) .
We also developed a tamoxifen-inducible Cre-dependent lentivirus expressing MCT1 shRNA, and produced oligodendrocyte-specific MCT1 knockdown by injecting virus into the corpus callosum of transgenic mice expressing a tamoxifen-inducible Cre (CreER) under the transcriptional control of myelin proteolipid protein (PLP1) ( Supplementary Fig. 10a) 35, 36 . Viral transfection of corpus callosum oligodendroglia was confirmed in control mice by co-localization of GFP with both CC-1-an antibody against adenomatous polyposis coli that labels oligodendrocytes-and MCT1 reporter (Supplementary Fig. 10b-g; arrowheads) . In tamoxifen-treated PLP1-CreER mice, the GFP reporter was excised in oligodendroglia, so specific viral localization of GFP to oligodendroglia is generally not visualized. There was clear axonal degeneration near the injection site in the PLP1-CreER mice, as demonstrated by SMI-32-immunoreactive axon swellings ( Supplementary Fig. 14k -m, boxed areas) and by axonal beading in GFP-labelled axons ( Supplementary Fig. 14n ), which was not observed when the identical virus was injected into wild-type mice ( Supplementary Fig. 14h-j) . Thus, in vivo oligodendrocyte-specific downregulation of MCT1 in both the optic nerve and the corpus callosum was capable of producing axon degeneration. Overall, these studies confirm that oligodendrocyte MCT1 is crucial for axon survival as loss of lactate transport from oligodendroglia to axons causes axon degeneration in both viral knockdown experiments and MCT1 1/2 mice.
MCT1 expression is reduced in ALS
Recent studies suggest oligodendroglia or their precursors may be injured in mutant SOD1 transgenic mice 18 . We proposed that the reduced ability of grey and white matter oligodendroglia to support motoneurons, caused by altered MCT1 expression, may contribute to ALS pathogenesis as seen in our in vitro and in vivo studies described earlier. We investigated the expression levels of MCT proteins and the MCT-associated protein CD147 (also known as BSG or basigin) in affected (that is, motor cortex) and unaffected (that is, frontal cortex) regions from patients with ALS and control patients. In addition, we investigated MCT1 reporter activity in the spinal cord of SOD1(G93A) transgenic mice-a commonly used model of ALS that had been crossed with MCT1-tdTomato BAC reporter mice. The motor cortex of patients with ALS showed a greater than 50% decline in MCT1 and MCT4 expression (P , 0.01 and P , 0.001, respectively) compared with gender-and age-matched control patients RESEARCH ARTICLE ( Fig. 6 and Supplementary Table 1 ). This reduction was not seen in the unaffected frontal cortex, nor was it seen for CD147, an accessory glycoprotein that increases the localization of MCT1 and MCT4 to the plasma membrane 37 (full blots available in Supplementary Figs 12 and  13 ). Oligodendroglia were still present in the cortical samples as there was no significant alteration in CNP (Fig. 6a, b) , although it is possible the oligodendroglia were immature.
In addition to patients with ALS, downregulation of MCT1 mRNA was also seen in the spinal cords of early symptomatic (Supplementary Fig. 11 ) and end-stage ( Fig. 6 ) SOD1(G93A) transgenic mice. SOD1(G93A) transgenic mice were mated to MCT1 BAC mice, and MCT1 mRNA expression was evaluated by tdTomato fluorescence. In SOD1(G93A) transgenic mice, MCT1 reporter continued to exclusively label oligodendroglia throughout the brain, although there was a marked reduction in MCT1 expression in the ventral horn grey matter (outlined by dashes, Fig. 6d , e) as compared with age-matched control mice (Fig. 6f, g) . Reduced MCT1 reporter expression was not due to less oligodendroglia, because CC-1-positive oligodendroglia were preserved, although again CC-1 immunoreactivity may not be labelling fully mature oligodendroglia (Fig. 6e ). Taken together, these results suggest that alterations in oligodendrocyte MCT1 may contribute to motoneuron degeneration in ALS, and provide a human disease in which downregulation of MCT1 is associated with neurodegeneration.
Discussion
Our results suggest that oligodendroglia support of axons, through MCT1-based transport of lactate (or pyruvate), is crucial for maintaining axon function and neuron survival and seems to be a fundamental property of oligodendroglia. Disruption of MCT1 could hypothetically cause either reduced lactate export out of, or reduced import into, oligodendroglia because the direction of transport is determined by the relative intra-and extracellular concentrations of lactate and hydrogen ions 6 . Our results suggest primarily disruption of lactate export. First, exogenous lactate completely prevents cell loss in organotypic cultures by compensating for reduced lactate export. Second, oligodendroglia do not degenerate in MCT1 1/2 mice or when exposed to MCT1 inhibitor and glucose deprivation in organotypic spinal cord cultures. Third, our study and others 10 demonstrate that MCT1 is predominantly localized to the myelin sheath around CNS axons, as expected for a transporter from oligodendroglia to axons. Taken together, our results suggest that MCT1-regulated lactate export from oligodendroglia is a crucial component of the local energy supply to axons, and the disruption of this transport leads to axon dysfunction and ultimately to neuron degeneration. Oligodendrocyte support of axons was also suggested by a recent paper that found increased brain lactate in transgenic mice with a selective deficit in oligodendroglia mitochondrial function 5 . Of course, lactate may also be imported into oligodendroglia and contribute to the production of myelin, as has been shown in dissociated 38 and cortical slice cultures 39 , but attenuation of MCT1 does not seem to cause neuron or axon degeneration through this mechanism.
Our results contribute to the emerging data that oligodendroglia are implicated in ALS pathogenesis. Spinal cord ventral grey matter oligodendrocyte precursor cells markedly replicate in ALS mouse models 18 , possibly in response to oligodendroglial injury (J.D.R., unpublished data), and cytoplasmic inclusions are found in human ALS oligodendroglia 40 . We found that MCT1 is reduced in affected brain regions from patients with ALS and the ventral horn of the spinal cord in mutant SOD1 transgenic mice. These changes could reflect downregulation of the transporter within intact oligodendroglia, or perhaps death of oligodendroglia and replacement with immature oligodendroglia. Newly generated oligodendroglia, labelled with CC-1, do not contain MCT1 (Fig. 6) , and would therefore be unable to supply energy metabolites to axons, leading to axon injury and neuron loss. We propose that this mechanism contributes to motoneuron degeneration in ALS. Future experiments will investigate this specifically by determining whether MCT1 downregulation is specific for ALS and whether MCT1 upregulation or transplantation of oligodendroglia can prolong survival in ALS mouse models.
METHODS SUMMARY
MCT1 BAC mice were developed and MCT1 expression was localized to specific cells by crossing with cell-specific reporter lines, immunostaining for cell-specific markers, or isolating mRNA by FACS and BacTRAP. Critical function of oligodendrocyte MCT1 was evaluated in vitro in organotypic spinal cord cultures, and in vivo in MCT1 1/2 or wild-type mice injected with lentiviral vectors. Neuronal toxicity, measured by loss of neurofilament-containing neurons and incorporation of propidium iodide, was provoked in organotypic cultures by treating with ASO or MCT1i. MCT1 1/2 mice were evaluated by histology, immunohistochemistry and electron microscopy, and compared with littermate controls. For lentiviral experiments, MCT1 shRNA was subcloned into lentivirus plasmid along with three different promoters (that is, H1, MBP and Cre-dependent V6). Lenti-shRNA, which expresses MCT1 shRNA driven by the H1 promoter and GFP by the CMV promoter, was injected into the spinal cord of C57Bl6 wild-type mice and motoneurons in the vicinity of virus were counted and compared with control virus injections. Lenti-MBP-shRNA was injected into the optic nerve of Sprague-Dawley rats, and degenerating axons were quantified by electron microscopy and compared with the contralateral optic nerve injected with control virus. Cre-dependent lenti-V6-shRNA was injected into the corpus callosum of PLP1-CreER mice, and axon pathology was assessed by non-phosphorylated neurofilament immunostaining. Finally, MCT1 expression was evaluated by western blots of cortex from patients with ALS and control patients; and MCT1 expression in SOD1(G93A) transgenic mice, obtained from Jackson laboratories, was evaluating by crossing these mice to MCT1 BAC reporter mice. 
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METHODS
Development of MCT1 BAC reporter and MCT1 overexpressor mice. MCT1-tdTomato BAC reporter mice were produced as described previously 22 . The BAC construct was modified to include the entire 19.8 kilobase (kb) MCT1 gene plus 50 kb upstream of the first exon and 132.2 kb downstream of the last exon ( Supplementary Fig. 2a ). Founder lines were identified by PCR (primer pair was 59-CGAGGAGGTCATCAAAGAGT-39 and 59-AGAACTTGAGGTGGTC CATC-39) and also by tdTomato fluorescence within red blood cells. Two expression lines were produced and backcrossed with B6 or C57BL/6 wild-type mice. To produce MCT1 overexpressor mice, the promoter for the astrocytespecific gene, Gfap, was used to drive MCT1 overexpression specifically in astrocytes 41 . MCT1 was inserted between the Gfap promoter sequence and an internal ribosomal entry site (IRES)-eGFP sequence, resulting in expression of MCT1 and eGFP together in astrocytes. Six founder lines were generated, of which five expressed MCT1 and eGFP within CNS astrocytes. Generation of lines coexpressing the MCT1 BAC reporter and other transgenes. GLT1-eGFP BAC 22 , MOBP-eGFP BAC (GENSAT), PLP1-eGFP (Jackson laboratory), PLP1-CreER (Jackson laboratory), CNP-eGFP/RPL10A (Jackson Laboratory), ALDH1L1 (GENSAT), Thy-I-yellow fluorescent protein (YFP) (Jackson laboratory), and SOD1 G93A transgenic mice (Jackson laboratory) were crossed with MCT1 BAC reporter mice to establish double transgenic mice. FACS, rtPCR and BacTRAP. Brains from 1-month-old MCT1-tdTomato BAC reporter mice were prepared as described previously 42 . Cells were sorted into three groups with a MoFlo MLS high-speed cell sorter (Beckman coulter) running Summit version 4.3 software in the FACS core at The Johns Hopkins University. Total RNA prepared from sorted cells and tissue using Absolutely RNA miniprep kit (Stratagene) was converted to complementary DNA using a cDNA synthesis kit (Applied Biosystems). PCR for MCT1 or Actin (control) was completed using the following primer pairs: MCT1, 59-AAAATGCCACCTGCGATTG GA-39 and 59-GCCTGATTAAGTGGAGCCAGG-39; Actin, 59-AGGCCAACCGTGA AAAGATG-39 and 59-CACAGCCTGGATGGCTACGT-39. TaqMan premade gene-specific probes and 18S ribosomal RNA (as a control) were used for rtPCR. For the FACS isolation of oligodendroglia and astrocytes in the brains, young adult MOBP-eGFP and GLT1-eGFP BAC mice (1-2 months) were used as described previously 42 . For affinity purification of polysomal mRNAs from oligodendroglia and astrocytes in the brain, adult CNP BacTRAP (translating ribosome affinity purification) and ALDH1L1 BacTRAP mice were used, respectively, as described previously 43 . Primary antibodies for western blots and immunohistochemistry. Detailed protocols for western blots and immunohistochemistry are described below.
The following primary antibodies were used for western blots: human MCT1 (AbGent; 1:75), mouse MCT1 (Santa Cruz; 1:50), MCT4 (Millipore; 1:400), CD147 (Novus Biologicals; 1:500), CNP (Millipore; 1:1,000), Connexin 43 (Millipore; 1: 500), and b-actin (Millipore; 1:1,000). The following primary antibodies were used for immunofluorescence: mouse MCT1 (Santa Cruz; 1:50), human MCT1 (Santa Cruz; 1:50), OLIG2 (Millipore; 1:500), CC-1 (Calbiochem; 1:50), CNP (Millipore; 1:250), MBP (Covance; 1:250), PDGFRa (BD Pharmingen; 1:100), NG2 (Millipore; 1:100), GFAP (Dako; 1:2,000), IBA1 (Wako; 1:500), NeuN (Millipore; 1:250), SMI-32 (Covance; 1:1,000) ubiquitin (Millipore; 1:250), CASPR (from D. Bergles; 1:1,500), Nav1.6 (from D. Bergles; 1:100), DsRed (Clontech; 1:250), TUJ1 (Millipore; 1:1,000), NeuN (Millipore; 1:1,000) and ALDH1L1 (Neuromab/UC Davis; 1:10). Lactate uptake assay in oligodendroglioma and astrocytoma cell lines. MO3.13 oligodendroglioma and U87 astrocytoma cell lines are cultured as described in previous reports 44, 45 . The lactate uptake assay was completed as described previously 46 with only small modifications. In brief, cells were incubated with 0.5 mCi ml 21 To assess neuropathology by light microscopy, tissue sections were stained with haematoxylin and eosin, eriochrome staining, Bielschowsky silver-staining, or immunohistochemistry. For lectin staining of endothelial cells, biotinylated Lycopersicon esculentum lectin (Vector Laboratories; 1:200) was incubated with sections for 1 h. As a secondary antibody, sections were incubated in streptavidin-488 (Vector Laboratories; 1:100). For immunohistochemistry of MCT1, tissue slices were pre-treated with sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) for antigen retrieval (other primary antibodies did not require antigen retrieval) before 1 h incubation at room temperature in blocking buffer (0.3% BSA, 5% skimmed milk and 0.3% Triton-X 100 in PBS). Primary antibodies were incubated overnight at 4 uC, washed and then incubated for 2 h at room temperature in anti-mouse or anti-rabbit IgG Alexa-fluor secondary antibodies (Invitrogen; 1:200). Photomicrographs were taken on Zeiss LSM510 meta confocal microscopy or Zeiss image Z1 fluorescent microscopy. Co-labelled cells with either immunostaining or transgenic reporters were manually counted in Axiovision from digital images taken by fluorescent microscopy. For electron microscopy, 1-mm thick sections were stained for toluidine blue and examined under light microscopy with 3100 oil-immersion objective. Thin sections (70 nm) were obtained and stained for citrate/uranyl acetate. For quantification of axon degeneration in the optic nerves of MCT1 heterozygous mice and mice treated with lenti-MBP-shRNA, three and ten 37,000 electron micrographs, respectively, were acquired for each optic nerve using a Zeiss Libra transmission electron microscope. The total number of axons and degenerating axons, as defined by degenerating myelin or dark axons, on each electron micrograph was counted and the percentage of axonal degeneration calculated. All quantification was completed by an investigator blinded to the genotype or treatment group. Production of cell cultures. Oligodendrocyte cultures were produced from postnatal day (PND) 2-3 mouse cortical tissues of PLP1-eGFP 3 NG2-tdTomato double transgenic mice. In brief, oligodendrocyte progenitor cells (OPCs) were isolated by FACS and maintained in OPC culture medium (SATO medium containing PDGFRa) for 4 days. OPCs were further differentiated into mature oligodendroglia in the differentiation media (SATO media containing T3 without PDGFRa).
Primary astrocyte cultures were produced from PND 2-3 mouse pups. Cortices were dissected out and dissociated with papain and subsequently cultured on collagen-coated T75 flask in DMEM containing 10% FBS. At 14 days in vitro (DIV) astroglial cells were seeded into collagen-coated 6-well plates at a concentration of 7 3 10 5 cells per well.
Organotypic or cortical spinal cord cultures were produced from PND 7 Sprague-Dawley rat pups or MCT1-tdTomato reporter mice, as described previously 47 . ASOs or MCT1i treatment in organotypic spinal cord cultures. One week after plating organotypic spinal cord cultures, 5 mM MCT1 ASO (IDT) or various doses of MCT1i were added to media for 3 weeks. Sections were either visualized with propidium iodide (7.5 mM, 2 h, Sigma) or fixed with 4% paraformaldehyde, and immunostained with the neuronal marker SMI-32 (Covance; 1:1,000). Large, ventral horn SMI-32-positive neurons were counted by an investigator blinded to the treatment condition. MCT1i and glucose deprivation in organotypic spinal cord cultures. Two weeks after collection, cultures were pre-treated with MCT1i (ref. 27) or DMSO for 24 h, incubated in propidium iodide for 2 h, and then photographed on a Nikon epifluorescence scope (pre-treatment). Sections were then washed, incubated with glucose-free or normal buffer with or without MCT1i for 2 h, allowed to recover for 2 h, re-incubated with propidium iodide for 2 h, and photographed images were quantified by fluorescent intensity (post-treatment). To examine motoneuron loss, sections were returned to normal media for 2 weeks, fixed in 4% paraformaldehyde, and immunostained with SMI-32 (Covance, 1:1,000). To study cellular localization of propidium iodide, sections were immediately fixed in 4% paraformaldehyde and then processed for immunocytochemistry with primary antibodies. Secondary antibodies used for detection were AlexaFluor 488-conjugated goat anti-rabbit, anti-mouse or antichicken antibodies (Invitrogen; 1:1,000). Organotypic spinal cord cultures treated with bicuculline or glutamate. For bicuculline (BIC) experiment, spinal cord slice cultures (2 weeks post-culture) were treated with 100 mM BIC (or vehicle) in the presence or absence of 1 mM MCT1i for 3 days. To measure cell death, cultures were incubated with propidium iodide and then photographed on a Nikon epifluorescence scope. For glutamate experiment, spinal cord cultures were incubated with MCT1i (or DMSO vehicle for controls) for 24 h, followed by media with or without 250 mM glutamate buffer for 60 min. Propidium iodide staining was performed before and after the glutamate treatment to visualize dead cells. For quantification, fluorescent intensities of pre-treatment sections measured by Image J software for the dorsal ARTICLE RESEARCH horn in BIC-treated sections, and total spinal cord in glutamate treated sections, were subtracted from post-treatment sections. All values were normalized to untreated control sections. Production of lentiviral constructs. On the basis of pre-designed ON-TARGETplus SMARTPool siRNA sequences (Dharmacon), DNA oligonucleotides that contain MCT1 shRNA sequences were synthesized and directly subcloned into pSuper vector (Oligoengine). The sense and antisense oligonucleotide sequences for the most efficient MCT1 shRNA were as follows: 59-GATCCC CGTATCATGCTTTACGATTATTCAAGAGATAATCGTAAAGCATGATAC TTTTTTC-39, 59-TCGAGAAAAAAGTATCATGCTTTACGATTATCTCTTG AATAATCGTAAAGCATGATACGGG-39.
DNA fragments spanning the H1 promoter and the shRNA sequences in pSuper construct were amplified by PCR and subcloned into FUGW-CMV to produce lenti-shRNA (in which MCT1 shRNA is driven by the H1 promoter and GFP by the CMV promoter). Fragments spanning MBP promoter, shRNA and IRES-eGFP sequences were subcloned into FUGW-CMV to produce lenti-MBP-shRNA. V6::MCT1 shRNA was subcloned into the HpaI and XhoI restriction sites of pSico (Addgene) to produce Cre-inducible lentivirus. Lentiviral constucts, including control GFP constructs, were produced in HEK293 T cells using the FUGW-CMV/D8.9/VSVG system. MCT1 shRNA lentivirus injected into spinal cord. Unilateral injections of lenti-shRNA (n 5 10) or lenti-GFP (n 5 8) were performed in C57BL6 wild-type mice at 100 days of age at cervical spinal cord levels 4-6 (C4-6), delivering 1.7 3 10 5 plaque-forming units (p.f.u.) for lenti-GFP or 1.8 3 10 5 p.f.u. for lenti-shRNA per mouse. In brief, the transverse processes of C4-6 were removed, the dura removed, and three 1-ml injections of lentivirus or media were injected with a 34-gauge Hamilton syringe needle. Animals were euthanized after 4 weeks by transcardial perfusion with 4% paraformaldehyde. Spinal cord sections were cryoprotected, sectioned on a cryostat, and immunostained for neurofilaments (SMI-32), oligodendrocyte-lineage cells (OLIG2), microglia (IBA1) or astrocytes (GFAP), as described earlier. Large (diameter greater than 20 mm) neurofilamentcontaining neurons in the ventral spinal cord were counted from every third section that localized GFP to the ventral horns on both the virus-and mediainjected halves of the spinal cord (mean number of sections counted 11.9 for shRNA group and 12 for GFP group). For each animal, the mean number of motoneurons per section from the virus-injected spinal cord hemisection was divided by the mean number of motoneurons per section from the contralateral media-injected motor neurons per section. Generation of heterozygous MCT1-null mice. Heterozygous MCT1-null mice were generated by targeted homologous recombination to replace a 640-base-pair sequence of the MCT1 gene starting at the translation initiation codon and containing exon 1 as well as part of the first intron with the LacZ gene sequence fused with a neomycin (Neo) resistance gene sequence and put in frame with the MCT1 promoter (S. Lengacher et al., manuscript in preparation). Successful recombination event and proper insertion of the LacZ/Neo sequence in the targeted locus was controlled by Southern blot on DNA from embryonic stem cells previously electroporated with the targeted vector and selected with gancyclovir and G418. Genotyping of animals was performed by PCR with appropriate set of primers. MCT1 shRNA driven by MBP promoter injected into rat optic nerves. Sixtyday-old Sprague-Dawley rats were anaesthetized with 2% isofluorane, an incision placed in the scalp overlying the orbital ridge, the skin overlying the orbital ridge retracted, and a conjunctival suture placed to provide traction to the globe. The optic nerve was localized, a window cut in the overlying dura, the nerve pierced with a pulled micropipette, and each nerve infused with 3 ml of either lenti-MBP-shRNA or lenti-MBP-GFP (2.4 3 10 11 virus particles per ml). After 4 weeks, the rats were transcardially perfused with 4% paraformaldehyde and the optic nerves from the globe to the optic chiasm carefully dissected. The optic nerve near the injection site was post-fixed in 4% paraformaldeyde, cryoprotected in 25% sucrose and cut on a cryostat. These nerve segments were later immunostained with OLIG2, GFAP and SMI-32. Optic nerve distal to the injection was post-fixed in 4% paraformaldehyde, 2.5% glutaraldehyde for 3 days and then processed for electron microscopy as described earlier.
Cre-dependent MCT1 shRNA lentivirus injected into corpus callosum. Creinducible MCT1 shRNA lentivirus was injected bilaterally into the corpus callosum of PLP-CreER 36 , MCT1-tdTomato reporter, and wild-type mice at approximately 60 days of age. Mice were anaesthetized with ketamine and xylazine, placed in a stereotaxic device, and the corpus callosum injected bilaterally with 2 ml lentivirus (2.6 3 10 11 virus particles per ml), as previously described 48 . After 1 week, mice were injected intraperitoneally with 1 mg tamoxifen for 5 consecutive days to induce Cre recombination of nucleus-integrated virus. Mice were euthanized 4 weeks later by transcardial perfusion with 4% paraformaldehyde. Sections were cryoprotected, sectioned on a cryostat, and immunostained for neurofilaments (SMI-32) and GFP, as described above. Western blotting of human autopsy samples, primary cells and mouse tissues. Autopsy samples were obtained from the Johns Hopkins University Brain Resource Center and the Johns Hopkins ALS Tissue Bank. Human or mouse samples were homogenized in TBS with 0.1% SDS, 1% Triton and 10% glycerol, primary cultures were lysed as described previously 49 . Western blotting and densitometry was performed using the enhanced chemilluminescence (ECL) system (GE Healthcare) and NIH Image J. Statistics. In-vitro ASO and MCT1i experiments were analysed using one-way ANOVA followed by Tukey-Kramer post-hoc test. Western blots, rtPCR, and in-vivo lenti-shRNA quantifications were analysed using unpaired Student's t-tests. Quantification of axon degeneration in lentivirus injections of optic nerve was evaluated with a Mann-Whitney test.
